Effect of Simultaneous Treatment with Royal Jelly and Doxorubicin on the Survival of the Prostate Cancer Cell Line (PC3): An In Vitro Study

Abandansari, Rouzbeh Mohammadi; Parsian, Hadi; Kazerouni, Faranak; Porbagher, Roghaye; Zabihi, Ebrahim; Rahimipour, Ali

doi:10.5812/ijcm.13780

Cited by 10 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In regard to anticancer effects of royal jelly, Nakaya et al have shown that RJ has anticancer effects by suppression of the estradiol-induced cell proliferation of MCF-7 breast cancer cells [ 28 ]. Mohammadi Abandansari et al have reported that RJ especially at the concentrations of 50 and 100 mg/mL significantly showed the cytotoxic activity against the prostate cancer cell line [ 29 ]. Recently, in a randomized double-blind clinical trial, Miyata et al have revealed that oral administration of capsules having 900 mg royal jelly considerably reduces the tumor size and some adverse side effects such as fatigue and anorexia in patients with renal carcinoma [ 30 ].…”

Section: Resultsmentioning

confidence: 99%

Antitumor Activity of Royal Jelly and Its Cellular Mechanisms against Ehrlich Solid Tumor in Mice

Albalawi

Althobaiti

Alrdahe

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Objective. The present study was aimed at evaluating the antitumor effects of royal jelly (RJ) obtained from Apis mellifera compared with cyclophosphamide against the Ehrlich solid tumors (EST) in mice. Methods. Tumor growth inhibition, body weight, the serum level of alpha-fetoprotein (AFP) and carcinoembryonic antigen tumor (CAE), liver and kidney enzymes, tumor lipid peroxidation (LPO), nitric oxide (NO), antioxidant enzymes (glutathione peroxidase (GPx), catalase enzyme (CAT), and superoxide dismutase enzyme activity (SOD)), tumor necrosis factor alpha level (TNF-α), and the apoptosis-regulatory genes expression were assessed in EST mice treated with RJ (200 and 400 mg/kg orally once a day for 2 weeks). Results. The results showed that treatment of EST-suffering mice with RJ at the doses of 200 and 400 mg/kg causes significant reduction in tumor volume and inhibition rate, body weight, tumor markers (AFP and CEA), serum level of liver and kidney, LPO and NO, TNF-α level, as well as the expression level of Bcl-2 in comparison with the EST mice receiving the normal saline; whereas RJ at the doses of 200 and 400 mg/kg/day significantly increased ( p < 0.05 ) the level of antioxidant enzymes of GPx, CAT, and SOD and the expression level of caspase-3 and Bax genes. Conclusion. The findings revealed that oral administration of royal jelly especially at the doses of 200 and 400 mg/kg exhibited promising antitumor effects against EST in mice through induction of apoptosis as well as its antioxidant and anti-inflammatory effects, which suggest it as a novel anticancer agent against tumor; however, additional surveys especially in clinical setting are necessary to approve these findings.

show abstract

Section: Resultsmentioning

confidence: 99%

Antitumor Activity of Royal Jelly and Its Cellular Mechanisms against Ehrlich Solid Tumor in Mice

Albalawi

Althobaiti

Alrdahe

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Based on previous investigations of the chemical composition of RJ, free fatty acids, such as the hydroxyl and dicarboxylic acids, are the key lipids of dry RJ [ 9 , 10 ]. 10-HDA is one of the principle fatty acids in RJ and displays a number of pharmacological and therapeutic effects, e.g., antioxidant, anti-inflammatory, anti-tumor, boosting immunity system, and antimicrobial activities [ 14 , 15 , 16 , 17 ]. Here, we assessed the anti-cancer effects of 10-HDA and investigated its cellular mechanisms against the human hepatoma cell line HepG2 in comparison with DOX.…”

Section: Discussionmentioning

confidence: 99%

“…Among these bioactive compounds, the lipids comprise nearly 5–20% of RJ volume, with >90% of these lipids reported as hydroxyl or dicarboxylic fatty acids [ 11 ]. Queen bee acid (10-Hydroxy-2-Decenoic Acid, 10-HDA) is well-known as a lipid constituent or fatty acid in RJ [ 12 , 13 ] that exhibits numerous pharmacological and therapeutic effects, e.g., antioxidant, anti-inflammatory, anti-tumor, immune boosting, and antimicrobial activities [ 14 , 15 , 16 ]. Recently, Alnomasy et al [ 17 ] showed the promising anti-cancer effects of royal jelly against human hepatoma cells (HepG2) via the induction of apoptosis through different pathways; however, the anti-cancer effects of specific compounds from RJ (such as 10-HDA) against human hepatoma cells have not yet been determined.…”

Section: Introductionmentioning

confidence: 99%

Anti-Cancer Effects of Queen Bee Acid (10-Hydroxy-2-Decenoic Acid) and Its Cellular Mechanisms against Human Hepatoma Cells

2023

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is the most common form of liver cancer that occurs in hepatocytes. Although many chemical drugs, e.g., cisplatin, methotrexate, taxis, and doxorubicin are used to treat HCC, there have been numerous reports related to the side effects of these drugs (e.g., emerging drug resistance, bone marrow failure, and gastrointestinal disorders). These issues led scientists to search for the novel anti-cancer drugs, mainly in natural products with greater efficiency and less toxicity. The current survey was intended to assess the anti-cancer effects of queen bee acid (10-Hydroxy-2-Decenoic Acid, 10-HDA) and its cellular mechanisms against the human hepatoma cell line HepG2. Materials and Methods: The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay was used to evaluate the effect of 10-HDA on the viability of HepG2 cells. The initial and late apoptosis in the HepG2 cells treated with 10-HDA were assessed by the Annexin-V (AV) assay. The level of the gene and protein expression of some apoptosis genes (e.g., caspase-3, Bcl-2-associated X protein (BAX), and B-cell lymphoma protein 2 (Bcl-2)), Poly (ADP-ribose) polymerases (PARP), and miRNA-34a (miR-34a), were measured by real-time PCR and Western blot. Results: The obtained findings revealed that HepG2 cell viability was markedly reduced (p < 0.01) following exposure to 10-HDA in a dose-dependent matter. The calculated half maximal cytotoxic concentration (CC50) value of 10-HDA was 59.6 µg/mL for HepG2 cells, while this value for normal THLE-3 cells was 106.4 µg/mL. We found that 10-HDA markedly elevated (p < 0.01) the percentage of necrotic and apoptotic cells from 0.94 to 9.7 and 27.6%, respectively. The real-time PCR results showed that the expression levels of the caspase-3, Bax, and miR-34a genes were significantly (p < 0.001) elevated. Contrary to these results, a significant (p < 0.01) reduction in the expression level of the Bcl2 gene was observed. The levels of protein expression of Caspase-3, PARP, and Bax were markedly elevated following exposure of HepG2 cells to 10-HDA at ¼ CC50, ½ CC50, and CC50. The level of protein expression of Bcl-2 was markedly reduced following exposure of HepG2 cells to 10-HDA at ¼ CC50, ½ CC50, and CC50 (p < 0.01). Conclusion: The current results confirmed the potent in vitro cytotoxic effects of 10-HDA on HepG2 cells with no significant cytotoxic effects on normal cells. Although its mechanisms of action have not been fully studied, the induction of apoptosis via different pathways was determined as one of the principle mechanisms of action of 10-HDA against HepG2 cells. Nevertheless, additional surveys must be performed to clearly understand the mechanisms of action and safety of this fatty acid.

show abstract

“…Some researchers have proposed the cytotoxicity of royal jelly on MRC-5 [ 35 ] and PC3 cell lines [ 36 ]. In the present study, this compound represented appropriate cytotoxicity in the HT-29 cell culture medium, as one of the most resistant and invasive cancer cell lines.…”

Section: Discussionmentioning

confidence: 99%

In Vitro and In Vivo Antioxidant and Anticancer Potentials of Royal Jelly for Dimethylhydrazine-Induced Colorectal Cancer in Wistar Rats

Khoob

Hosseini

Kazemi

2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Background and Objective. Royal jelly (RJ) is one of the well-known natural substances exhibiting great anticancer and antioxidant activities. Methods. This study was conducted among 60 rats, and groups consist of control, three separate groups for RJ, dimethylhydrazine (DMH), and vitamin E, and two separate treated groups with DMH + RJ and DMH + vitamin E. Additionally, the cytotoxicity of royal jelly was examined on HT-29 cell line. Findings. Based on the in vitro assessment using MTT assay, the LC50 of royal jelly was 1.781 mg/ml, and the highest cytotoxicity was observed at 25 mg/ml concentration after 48 hours. Meanwhile, in the in vivo study, after the 13th week, compared to the DMH group, the rats exposed to DMH + royal jelly experienced a significant less oxidative stress ( P < 0.05 ) and a significantly greater total antioxidant capacity (TAC) level ( P < 0.05 ). The expression of proliferating cell nuclear antigen (PCNA), platelet-derived growth factor (PDGF), and carcinoembryonic antigen (CEA) proteins significantly decreased among the animals receiving DMH + royal jelly compared to the DMH group. The pathological examinations revealed less congestion, necrosis, inflammation, and cell proliferation in the colon tissue of the RJ-treated group than that of the DMH group. Overall, the biochemical indices were better in the treatment groups in comparison with the DMH group. Conclusion. The results represented the clinical usability of royal jelly, as a substance with anticancer properties, to prevent and treat colorectal cancer. This issue is related to its effective antioxidant potential, which even exhibits more effectiveness than the vitamin E, which is known as a strong antioxidant.

show abstract

Effect of Simultaneous Treatment with Royal Jelly and Doxorubicin on the Survival of the Prostate Cancer Cell Line (PC3): An In Vitro Study

Cited by 10 publications

References 15 publications

Antitumor Activity of Royal Jelly and Its Cellular Mechanisms against Ehrlich Solid Tumor in Mice

Antitumor Activity of Royal Jelly and Its Cellular Mechanisms against Ehrlich Solid Tumor in Mice

Anti-Cancer Effects of Queen Bee Acid (10-Hydroxy-2-Decenoic Acid) and Its Cellular Mechanisms against Human Hepatoma Cells

In Vitro and In Vivo Antioxidant and Anticancer Potentials of Royal Jelly for Dimethylhydrazine-Induced Colorectal Cancer in Wistar Rats

Contact Info

Product

Resources

About